End of Aduhelm’s road; Janet Woodcock exit interview; Stuart Schreiber's $500M experiment; Vertex's pain breakthrough; and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.
Amid a week packed with earnings and big news, the Endpoints team also brought a solid lineup of original reporting. See if you missed anything!
End of Aduhelm’s road
Biogen will stop sales and development of its controversial Alzheimer’s drug Aduhelm, walking away from a drug that was approved against outside experts’ advice, led to congressional inquiries and faced pushback over its cost and efficacy.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.